A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home Archive for category "Treated Conditions" (Page 2)
formats

Medtronic Reports CRM AIMD Sales Trend Showing Stabilization + Strong Earnings from Neuromodulation AIMDs

Medtronic released today its earning reports for the second quarter of fiscal year 2014, which ended October 25, 2013. Medtronic states in the press release: “Second quarter revenue from Implantable Cardioverter Defibrillators (ICDs) was $713 million, an increase of 4 percent on a constant currency basis in a market that continues to show a trend

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Reports CRM AIMD Sales Trend Showing Stabilization + Strong Earnings from Neuromodulation AIMDs  comments 
formats

NeuroPace Receives FDA PMA Approval for for the RNS System to Treat Refractory Partial Epilepsy

NeuroPace is a privately-held company in Mountain View, CA. Their RNS® implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. On November 14, 2013, NeuroPace has now received FDA pre-market approval for the NeuroPace RNS System as a treatment for adults with partial onset

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on NeuroPace Receives FDA PMA Approval for for the RNS System to Treat Refractory Partial Epilepsy  comments 
formats

Interesting Article in Medical Design Briefs: Designing an ASIC Chip to Control an Implantable Glucose Measurement Device

The current issue of Medical Design Briefs carries an interesting article titled “Designing an ASIC Chip to Control an Implantable Glucose Measurement Device” by Uwe Guenther of ZMDI (Dresden, Germany) and Andrew DeHennis of Senseonics (formerly known as “Sensors for Medicine and Science, Inc.” in Germantown, MD). Zentrum Mikroelektronik Dresden AG (ZMDI), Dresden, Germany, partnered

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Interesting Article in Medical Design Briefs: Designing an ASIC Chip to Control an Implantable Glucose Measurement Device  comments 
formats

Nyxoah Developing Implant for Obstructive Sleep Apnea and Snoring

Nyxoah was founded in 2009 by Robert Taub and Dr. Adi Mashiach to develop neurostimulation treatments focused for Obstructive Sleep Apnea. Nyxoah is currently engaged in clinical tests of a tiny, battery-less implantable neurostimulator that can electrically control the nerves of the tongue and so prevent airway blockage. According to Nyxoah, the implantable device is

 
Tags:
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Nyxoah Developing Implant for Obstructive Sleep Apnea and Snoring  comments 
formats

Neuros Medical Receives IDE Approval to Conduct Pivotal Study

Neuros Medical received an Investigational Device Exemption to conduct a pivotal clinical trial to evaluate the Altius™ System High Frequency Nerve Block technology for the management of intractable limb pain of amputees.   The prospective, randomized, controlled pivotal clinical trial will consist of 130 patients at 15 institutions in the U.S. to evaluate the safety and

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Neuros Medical Receives IDE Approval to Conduct Pivotal Study  comments 
formats

St. Jude Acquires Nanostim, Announces CE Mark of World’s First Leadless Pacemaker

St. Jude Medical today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers. The acquisition adds the world’s first and only leadless pacemaker to the St. Jude Medical product portfolio. According to the press release: Unlike conventional pacemakers that require a more invasive surgery, the Nanostim™ leadless pacemaker

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude Acquires Nanostim, Announces CE Mark of World’s First Leadless Pacemaker  comments 
formats

FDA Panel Majority Votes Against Effectiveness of CardioMEMS CHAMPION HF Monitoring Device

Although the FDA advisory panel found CardioMEMS’ CHAMPION HF Pressure Measurement System to be safe, on October 9, 2013, the majority of panel members decided that the implantable sensor monitor to help guide treatment in patients with congestive heart failure is not effective. According to Forbes, one panel member said it was difficult to connect the dots between

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on FDA Panel Majority Votes Against Effectiveness of CardioMEMS CHAMPION HF Monitoring Device  comments 
formats

MicroTransponder Raises Funds for Clinical Trials of Serenity VNS IPG for Treating Tinnitus

MicroTransponder, Inc. of Dallas, TX has raised $3.4 million to carry out clinical trials of its Vivistim System to help restore functionality in the upper limbs of stroke patients, and its Serenity System designed to “rewire” the auditory cortex of tinnitus patients. The company intends to secure a CE mark for both systems next year, and then

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on MicroTransponder Raises Funds for Clinical Trials of Serenity VNS IPG for Treating Tinnitus  comments 
formats

ElectroCore’s Noninvasive Vagus Nerve Stimulation – An Interesting Challenge to Implantable VNS Systems

Surgically accessing the Vagus Nerve is not trivial, and implanting a VNS system involving cuff electrodes is risky and recovery is lengthy.  Enter ElectroCore Medical of Bernards Township, New Jersey – it is developing non-invasive VNS therapies that treat or prevent symptoms of serious headache conditions, including migraines and cluster headaches, and bronchoconstriction including asthma and chronic obstructive

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on ElectroCore’s Noninvasive Vagus Nerve Stimulation – An Interesting Challenge to Implantable VNS Systems  comments 
formats

Interesting 2012 Presentation by Setpoint Medical on Neuromodulation for Treating Chronic Inflammatory Diseases

I found online the PowerPoint presentation for: R Zitnik, Y Levine, M Faltys, T Arnold, “Harnessing the Inflammatory Reflex: Using Neuromodulation as a Novel Approach to Treat Chronic Inflammatory Diseases”, North American Neuromodulation Society Meeting 2012. The presentation shows some preliminary animal results, presents an artist’s conception of the implantable system, and concludes as follows:

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Interesting 2012 Presentation by Setpoint Medical on Neuromodulation for Treating Chronic Inflammatory Diseases  comments 
formats

Cyberonics Reports 12.4% Increase in VNS Sales for Fiscal Q1 2014

Net product sales increased 12.4% to $67.4 million in the first fiscal quarter ended July 26 for Cyberonics, Inc. of Houston, TX. Including license revenue, sales were up 14.2% overall, with Europe in particular contributing a strong performance. Diluted earnings per share were adjusted by $0.17 cents due to a litigation settlement. According to the

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Cyberonics Reports 12.4% Increase in VNS Sales for Fiscal Q1 2014  comments 
formats

Autonomic Technologies’ Sphenopalatine Ganglion Stimulator Treats Cluster Headaches

Autonomic Technologies, Inc. (ATI) is a medical device company located in the San Francisco Bay Area focused on the development of neurostimulators for the treatment of severe headache. The company’s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache and is currently being investigated in a multi-center, randomized

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Autonomic Technologies’ Sphenopalatine Ganglion Stimulator Treats Cluster Headaches  comments 
formats

Cleveland FES Center’s Networked Neural Prosthesis

The Cleveland FES Center was established in 1991 as a consortium between the Cleveland VA Medical Center (CVAMC), the private educational institution of Case Western Reserve University (CWRU), and the public hospital system of MetroHealth Medical Center (MHMC). As part of this consortium, Dr. Hunter Peckham – biomedical engineering professor at Case Western Reserve University –

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Cleveland FES Center’s Networked Neural Prosthesis  comments 
formats

SetPoint Medical Secures $27M to Develop VNS Device to Treat Inflammatory Diseases

SetPoint Medical, headquartered in Valencia, California, is developing neuromodulation therapies for patients with inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, diabetes, heart disease, and multiple sclerosis. SetPoint’s proprietary neuromodulation platform consists of an implantable “microregulator”, wireless charger and iPad prescription pad application. SetPoint announced today that it has secured

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on SetPoint Medical Secures $27M to Develop VNS Device to Treat Inflammatory Diseases  comments 
formats

Medtronic Implants first Activa® PC+S DBS IPG Capable of Sensing and Recording Brain Activity While Delivering Therapy

Medtronic today announced the first implant of the novel Activa® PC+S deep brain stimulation (DBS) system that, for the first time, enables the sensing and recording of select brain activity while simultaneously providing targeted DBS therapy. According to the press release: This initiates research on how the brain responds to the therapy and could yield insights that

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Implants first Activa® PC+S DBS IPG Capable of Sensing and Recording Brain Activity While Delivering Therapy  comments